Thymosin Alpha-1
From PeptideSciences101, the open peptide reference. · Last updated: October 7, 2025
This article is a stub. A peer-reviewed deep-dive is in preparation. Help contribute to expand it.
…
Overview
Immune-modulating peptide that enhances T-cell function and supports overall immune health.
Reported benefits
Immune enhancement, antiviral properties, chronic infection support, cancer therapy adjunct
Protocols & dosing
Typical dosage: 1.6-3.2 mg (twice-weekly).
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Thymosin Alpha-1 is not currently FDA-approved for any indication. It is generally classified as a research compound. Regulatory status varies by country.
| Country | Status |
|---|---|
| United States | Research use only |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
Side effects & safety
Reported side effects: Well-tolerated. Rare: injection site reactions, mild flu-like symptoms
References
No external sources have been catalogued for this article yet.
Related peptides
- Actovegin — Tissue regeneration complex
- BPC-157 — Healing & recovery, gut health
- BPC-157 Stable — Stabilized BPC variant
- FGL (Fibroblast Growth-Like) — Neural repair peptide
- GHK-Cu — Wound healing, skin regeneration
- Ghrelinomimetic — Appetite and healing support
Categories: Healing & Recovery